News & Events

Q&A: Cell and gene processing moves forward through ‘experiential learning’

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioPharma-Reporter, discussing how increased manufacturing demand for cell and gene therapies is driving the growth of the viral vector supply market and the challenges that are still to be addressed.

The growing prevalence of cell and gene therapies in both the clinical and the commercial side of the biopharmaceutical industry is leading to increased demand for viral vectors, with companies within the contract manufacturing sector building their capacity to meet clients’ needs.

BioPharma-Reporter spoke to Colin about how companies in this sector are addressing the rising demand, how the lack of capacity is affecting the industry, and what are the other challenges that manufacturers face.

You can read the full Q&A here.

Get In Touch.

By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.